ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 896

Increased Rho Kinase (ROCK) Activity In Temporal Artery Biopsies From Patients With Giant Cell Arteritis (GCA)

Lindsay Lally1, Navneet Narula2, Alessandra B. Pernis3, Wei-Ti Huang4, Uzunma Udeh1 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Pathology, Weill Cornell Medical College, New York, NY, 3Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, 4Biostatistics, Hospital for Special Surgery, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biopsies, giant cell arteritis, histopathologic and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: ROCKs are implicated in the pathogenesis of many vascular diseases.  ROCK activation is associated with Th17 differentiation and production of Th17-associated cytokines, IL-17 and IL-21.  Th17 cells and related cytokines are present in increased levels in the vascular inflammatory infiltrate in active GCA.  ROCK activity in GCA is unknown.   The aim of this study was to assess ROCK activity in temporal artery biopsy (TAB) specimens in GCA versus controls.  

Methods: All TAB performed at a tertiary care center over a 5 year period were identified.  Charts were reviewed for clinical information; included subjects had TAB specimens and clinical information available.  Subjects were categorized according to 1990 ACR criteria and TAB status into 3 groups: GCA with positive TAB, GCA with negative TAB and age-sex-matched controls. 

Paraffin-embedded temporal artery specimens were stained for Phospho-Ezrin/Radixin/Moesin (pERM), a surrogate of ROCK activity, using immunohistochemical (IHC) stain.  IHC stained slides were reviewed by a pathologist blinded to clinical status.  Three separate areas (endothelium, adventitia and vaso vasorum) were scored for intensity of staining on a scale of 0-2 for total possible composite score of 6. Primary outcome was biopsy pERM intensity score in subjects with GCA compared to controls.      

Results: Nineteen subjects with GCA had positive TAB, 17 subjects had GCA with negative TAB and18 age-sex-matched controls were analyzed.  Mean age was 77.9±9.1years and 81.4% were female (Table1).  Biopsy pERM intensity scores ranged from 2-6 with 28.3% scores £4 and 72.2% of scores >4 (high).   79.4% of high scores occurred in GCA subjects compared to controls (p=0.0033).  Compared to controls, GCA subjects with either positive or negative TAB showed statistically significantly higher pERM intensity scores (p=0.035 and p=0.0083 respectively).  Adjusting for comorbid diabetes, hypertension, prednisone use, and statin use, GCA subjects still had significantly higher pERM intensity scores compared to controls (OR 7.3; 95%CI 1.9-25.9, p=0.0046). High score for diagnosis of GCA had sensitivity of 86%, specificity of 55.6%.  Comparing GCA with negative TAB to controls, high score had sensitivity of 90.4% and negative predictive value of 90.9%. 

Conclusion: Subjects with GCA had more intense pERM staining in TAB specimens compared to age and sex-matched controls regardless of whether TAB was positive or negative, independent of prednisone dose, statin use, or vascular comorbidities. In this population, high pERM staining score had a sensitivity comparable to what is reported as sensitivities of TAB routine histopathology itself and suggests it may be a useful adjunctive diagnostic tool especially in patients with suspected GCA and negative TAB.  The ROCK pathway warrants further investigation in GCA as inhibition of this pathway is a potential therapeutic target.  

Table 1

GCA (n=36)

Control (n=18)

P value

Biopsy Positive (n=19)

Biopsy Negative (n=17)

Age, yr± SD

78.4±9.2

76.6±7.9

78.4±10.5

0.81

Female, n (%)

14 (74)

16 (94)

13 (72)

0.2

Prednisone Dose mg, mean±SD

55.6±17.9

50.6±17.1

47.2±27.2

0.5

Hypertension, n (%)

8 (44)

10 (59)

12 (67)

0.39

Diabetes, n (%)

1 (6)

6 (35)

4 (22)

0.11

Statin, n (%)

5 (28)

8 (47)

11 (61)

0.13

IHC score

0.0159

≤4

4 (21)

1 (6)

10 (56)

>4

15 (79)

16 (94)

8 (44)


Disclosure:

L. Lally,
None;

N. Narula,
None;

A. B. Pernis,
None;

W. T. Huang,
None;

U. Udeh,
None;

R. F. Spiera,

Roche Pharmaceuticals, g,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-rho-kinase-rock-activity-in-temporal-artery-biopsies-from-patients-with-giant-cell-arteritis-gca/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology